Burgos Peláez R, Cuerda Compes MC, García-Luna PP, Martínez Faedo C, Mauri Roca S, Moreno Villares JM,et al . Teduglutida: revisión de su uso en el síndrome de intestino corto. Nutr Hosp. 2016 Jul 19;33(4):400.
DOI: 10.20960/nh.400
Wanden-Berghe C, Oller-Arlandis V, Domingo-Pueyo A. Estudio epidemiológico de la prevalencia del síndrome de intestino corto en España. Hosp. Domic. 2022 [Internet]. [Acceso 2022 Mar] ; 6 ( 1 ): 27-36.
DOI: 10.22585/hospdomic.v6i1.152
Seisdedos Elcuaz R, Mejías Trueba M, Rodríguez Ramallo H, Pérez Blanco JL, Pereira Cunill JL, García Luna PP. Evolución de los pacientes con nutrición parenteral domiciliaria: una revisión sistemática de los estudios disponibles [Evolution of patients with home parenteral nutrition: a systematic review of available studies]. Nutr Hosp. 2020 Jul 13;34(3):599-608
Jeppesen PB, Pertkiewicz M, Messing B, Iyer K, Seidner DL, O'keefe SJ, Forbes A, Heinze H, Joelsson B. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012 Dec;143(6):1473-1481.
DOI: 10.1053/j.gastro.2012.09.007
Schwartz LK, O'Keefe SJ, Fujioka K, Gabe SM, Lamprecht G, Pape UF,et al . Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel Syndrome. Clin Transl Gastroenterol. 2016 Feb 4;7(2).
DOI: 10.1038/ctg.2015.69
Seidner DL, Fujioka K, Boullata JI, Iyer K, Lee HM, Ziegler TR. Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 Study. Nutr Clin Pract. 2018 Aug;33(4):520-527
DOI: 10.1002/ncp.10092
Bioletto F, D’Eusebio C, Merlo FD, Aimasso U, Ossola M, Pellegrini M, et al. Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis. Nutrients. 2022 Feb 14;14(4):796.
DOI: 10.3390/nu14040796
Raghu VK, Binion DG, Smith KJ. Cost-effectiveness of teduglutide in adult patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria. Am J Clin Nutr. 2020 Jan 1;111(1):141–8.
DOI: 10.1093/ajcn/nqz269
National Institute for Health and Care Excellence,.Appraisal consultation document – teduglutide for treating short bowel syndrome March 2022 , Internet . (Acceso abril 2023) https://www.nice.org.uk/guidance/ta804/documents/129
Alfaro Martínez JJ , Álvarez de Frutos V .Cánovas Gaillemín B, Encinas Barrios C , Fraga Fuentes MD, García Manzanares A, et al Documento de Consenso: Teduglutida en el tratamiento del síndrome de intestino corto. Octubre de 2018. Grupo de trabajo SESCAM para documento de consenso de Teduglutida, Internet. (Acceso Abril 2023).https://sanidad.castillalamancha.es/sites/sescam.castillalamancha.es/files/documentos/farmacia/5.documento_de_consenso_sescam_teduglutida_2018.pdf
Pape UF, Iyer KR, Jeppesen PB, Kunecki M, Pironi L, Schneider SM, Seidner DL, Lee HM, Caminis J. Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials. Therap Adv Gastroenterol. 2020 Apr 20;13:1756284820905766
DOI: 10.1177/1756284820905766
Pevny S, Maasberg S, Rieger A, Karber M, Blüthner E, Knappe-Drzikova B, Thurmann D, Büttner J, Weylandt KH, Wiedenmann B, Müller VA, Bläker H, Pascher A, Pape UF. Experience with teduglutide treatment for short bowel syndrome in clinical practice. Clin Nutr. 2019 Aug;38(4):1745-1755
DOI: 10.1016/j.clnu.2018.07.030
Schoeler M, Klag T, Wendler J, Bernhard S, Adolph M, Kirschniak A, et al. GLP-2 analog teduglutide significantly reduces need for parenteral nutrition and stool frequency in a real-life setting. Ther Adv Gastroenterol [Internet]. 2018 Aug 30 [cited 2022 May 13];11:1756284818793343.
DOI: 10.1177/1756284818793343
Joly F, Seguy D, Nuzzo A, Chambrier C, Beau P, Poullenot F, et al. Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study. Clin Nutr Edinb Scotl. 2020 Sep;39(9):2856–62.
DOI: 10.1016/j.clnu.2019.12.019
Puello F, Wall E, Herlitz J, Lozano ES, Semrad C, Micic D. Long-Term Outcomes With Teduglutide From a Single Center. JPEN J Parenter Enteral Nutr. 2021 Feb;45(2):318–22.
DOI: 10.1002/jpen.1838
Solar H, Doeyo M, Ortega M, De Barrio S, Olano E, Moreira E, et al. Postsurgical Intestinal Rehabilitation Using Semisynthetic Glucagon-Like Peptide-2 Analogue (sGLP-2) at a Referral Center: Can Patients Achieve Parenteral Nutrition and sGLP-2 Independency? JPEN J Parenter Enteral Nutr. 2021 Jul;45(5):1072–82.
DOI: 10.1002/jpen.1983
Loutfy A, Kurin M, Shah R, Davitkov P. Characterization of American teduglutide consumers from 2015 to 2020: A large database study. J Parenter Enteral Nutr. 2022; 46:646-651.
DOI: 10.1002/jpen.2221
Greif S, Maasberg S, Wehkamp J, Fusco S, Zopf Y, Herrmann HJ, et al . Long-term results of teduglutide treatment for chronic intestinal failure - Insights from a national, multi-centric patient home-care service program. Clin Nutr ESPEN. 2022 Oct;51:222-230.
DOI: 10.1016/j.clnesp.2022.08.027
Hill S, Carter BA, Cohran V, Horslen S, Kaufman SS, Kocoshis SA, et al. Safety Findings in Pediatric Patients During Long-Term Treatment With Teduglutide for Short-Bowel Syndrome-Associated Intestinal Failure: Pooled Analysis of 4 Clinical Studies. JPEN J Parenter Enteral Nutr. 2021 Sep;45(7):1456–65.
DOI: 10.1002/jpen.2061
Ramos Boluda E, Redecillas Ferreiro S, Manrique Moral O, García Romero R, Irastorza Terradillos I, Nuñez Ramos R, et al. Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data. J Pediatr Gastroenterol Nutr. 2020 Dec;71(6):734–9.
DOI: 10.1097/MPG.0000000000002899
Chen K, Mu F, Xie J, Kelkar SS, Olivier C, Signorovitch J, et al. Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure. JPEN J Parenter Enteral Nutr. 2020 Jan;44(1):119–28.
DOI: 10.1002/jpen.1588
Jeppesen PB, Pertkiewicz M, Forbes A, Pironi L, Gabe SM, Joly F, et al . Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study. Clin Nutr. 2013 Oct;32(5):713-21.
DOI: 10.1016/j.clnu.2013.03.016
Martin A, Boehm V, Zappa M, Billiauws L, Bonvalet F, Nuzzo A, et al. Imaging as predictor of clinical response to teduglutide in adult patients with short bowel syndrome with chronic intestinal failure. Am J Clin Nutr. 2021 May 8;113(5):1343–50.
DOI: 10.1093/ajcn/nqaa412
Fujioka K, Jeejeebhoy K, Pape UF, Li B, Youssef NN, Schneider SM. Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide. JPEN J Parenter Enteral Nutr. 2017 Nov;41(8):1419-1422.
DOI: 10.1177/0148607116663481
Harpain F, Schlager L, Hütterer E, Dawoud C, Kirchnawy S, Stift J, Krotka P, Stift A MD. Teduglutide in short bowel syndrome patients: A way back to normal life? J Parenter Enteral Nutr. 2022;46:300-309
DOI: 10.1002/jpen.2272
Ukleja A MD, To C MD, Álvarez A MD, Lara LF MD. Long-Term Therapy With Teduglutide in perenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series. J Parenter Enteral Nutr. 2018;42:821-825
DOI: 10.1002/jpen.1149
Jeppesen PB, Shahraz S, Hopkins T, Worsfold A, Genestin E. Impact of intestinal failure and parenteral support on adult patients with short-bowel syndrome: A multinational, noninterventional, cross-sectional survey. JPEN J Parenter Enteral Nutr. 2022 Sep;46(7):1650-1659.
DOI: 10.1002/jpen.2372
P. BerghöferK.C. FragkosJ.P. BaxterA. ForbesF. JolyH. HeinzeS. LothM. PertkiewiczB. MessingP.B. Jeppesen12. Development and validation of the disease-specific Short Bowel Syndrome-Quality of Life (SBS-QoL) scale. Clin Nutr. 32 (2013) 789-796.
Pironi L. Translation of Evidence Into Practice With Teduglutide in the Management of Adults With Intestinal Failure due to Short-Bowel Syndrome: A Review of Recent Literature. JPEN J Parenter Enteral Nutr. 2020 Aug;44(6):968-978.
DOI: 10.1002/jpen.1757
Sowerbutts AM, Burden S, Griffiths J, Abraham A, Farrer K, Leahy G, et al. Glucagon-like peptide 2 analogues in the treatment of intestinal failure: A qualitative exploration of the views of patients and their families in decision making. Clin Nutr. ESPEN. 2021 Aug;44:263-269.
DOI: 10.1016/j.clnesp.2021.06.005
Cuerda C, Pironi L, Arends J, Bozzetti F, Gillanders L, Jeppesen PB, et al . Home Artificial Nutrition & Chronic Intestinal Failure Special Interest Group of ESPEN. ESPEN practical guideline: Clinical nutrition in chronic intestinal failure. Clin Nutr. 2021 Sep;40(9):5196-5220.
DOI: 10.1016/j.clnu.2021.07.002